The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival impact of lymphocytopenia during chemoradiation in locally advanced NSCLC patients treated with adjuvant durvalumab.
 
Monika Satoskar
No Relationships to Disclose
 
Songzhu Zhao
No Relationships to Disclose
 
Kenneth Chian
No Relationships to Disclose
 
Natalie Johns
No Relationships to Disclose
 
Alexander Rudich
No Relationships to Disclose
 
Adam Khorasanchi
No Relationships to Disclose
 
Lai Wei
No Relationships to Disclose
 
Jinesh Gheeya
No Relationships to Disclose
 
Logan Roof
No Relationships to Disclose
 
Asrar Alahmadi
Consulting or Advisory Role - Amgen; Catalyst Pharmaceuticals; Daiichi Sankyo; Jazz Pharmaceuticals
 
Regan Memmott
Consulting or Advisory Role - Ideology Health (Inst); Johnson & Johnson (Inst); Orion (Inst)
Research Funding - Iterion Therapeutics (Inst)
 
Jacob Kaufman
Consulting or Advisory Role - AstraZeneca
 
Carolyn Presley
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Onc Live; Regeneron
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; oncoc4; Perthera; Pfizer
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)
 
Peter Shields
Research Funding - Novartis (Inst)
 
David Carbone
Consulting or Advisory Role - Arcus Biosciences (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); InThought (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst)
Research Funding - Genentech (Inst)
 
Mingjia Li
No Relationships to Disclose
 
Dwight Owen
Honoraria - Chugai Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Nuvalent, Inc. (Inst); Onc.AI (Inst); Palobiofarma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Genentech